This article was originally published in RAJ Devices
Gerald F Masoudi has been named chief counsel for the US Food and Drug Administration. Mr Masoudi rejoins the food and drug division of the Department of Health and Human Services' Office of the General Counsel (OGC), which handles legal matters for the FDA, as associate general counsel/chief counsel. Since 2005, Mr Masoudi has been deputy assistant attorney general in charge of international, policy and appellate matters in the antitrust division of the Department of Justice. From 2004-2005, he was principal deputy associate general counsel for the OGC's food and drug division, serving for a time as acting associate general counsel.
You may also be interested in...
CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.